ZTS
Zoetis
Dividend / Cash flow
★ Quality 73/100Price today
$81.03
Current discount
+18.9%
charlieapp.co
We are reviewing the data for this asset. For now we are not showing the calculated value or the signal — both come back as soon as the review is done.
A monopoly position
This company has a competitive advantage so strong that its rivals find it practically impossible to replicate.
What this business is made of
Price vs Intrinsic Value
The line is the price month by month; the green band marks when it's undervalued (−20% off value). When the price drops in there, the discount is real, not opinion.
How many times the cash flow
Dividend / Cash flow · vs 97 peers
You pay 18.6x times this business's cash flow; its sector median is 26.7x.
15% below what Charlie thinks it's worth (21.4x) — that gap is your safety margin.
Why does Charlie give it 21.4x?
The multiple is how many times its cash flow the business is worth.
An average business of its kind is worth 26.7x. This one drops from there:
High debt. debt payments drain cash before it reaches you.
Monopoly position. an edge so strong that replicating it would take decades.
72% margin. it charges almost pure toll; it can raise prices without losing customers.
That's why it's worth 21.4x, less than the 26.7x average.
The business
El veterinario receta; Zoetis cobra. Dueños de mascotas no regatean con su perro.
Zoetis fabrica medicinas, vacunas y diagnósticos para animales: mascotas y ganado. Vende directo a veterinarios y ganaderos, con marcas como Apoquel y Cytopoint (dermatitis en perros), Simparica (parásitos) y Librela (dolor de artritis). Factura $9.5B con 72% de margen bruto.
Portafolio patentado, décadas de datos clínicos y una fuerza de ventas metida en cada clínica veterinaria. Un genérico puede copiar la molécula, pero no la confianza del veterinario ni la red de distribución. La medicina animal casi no sufre presión de aseguradoras: el dueño paga de su bolsillo y no discute.
Revenue history
From $7.8B to $9.5B in 4 years. The business grows steadily.
Where each $100 of sales goes
Revenue $9.5B · FY2025
Of every $100 in sales, $72 goes to costs and operations; $28 is left as net profit (28% margin).
Catalysts and risks
Expansión de Librela para artritis canina en EE.UU., lanzado 2023.
Humanización de mascotas: dueños gastan más en salud animal cada año.
Franquicia de dermatología (Apoquel/Cytopoint) creciendo doble dígito.
Apoquel pierde exclusividad de patente; llegan genéricos más baratos.
Deuda de $9B sin caja: menos margen ante tasas altas.
Competencia directa de Elanco y Boehringer Ingelheim en cada categoría.
Charlie's note
“Negocio excelente, margen de 72% y foso ancho. Pagas 21x por crecer 5% al año — justo, no regalado. La calidad se paga; solo que aquí no te la rematan.”
Analysis · August 2026
Charlie informs, it doesn't advise. No information should be taken as a recommendation to buy or sell.